Ovarian cancer (OC) mostly arises sporadically, but a fraction of cases are associated with mutations in BRCA1 and BRCA2 genes. The presence of a BRCA mutation in OC patients has been suggested as a prognostic and predictive factor. In addition, the identification of asymptomatic carriers of such mutations offers an unprecedented opportunity for OC prevention. This review is aimed at exploring the current knowledge on epidemiological and molecular aspects of BRCA-associated OC predisposition, on pathology and clinical behavior of OC occurring in BRCA mutation carriers, and on the available options for managing asymptomatic carriers.
BRCA-Associated Ovarian Cancer: From Molecular Genetics to Risk Management / Giulia Girolimetti;Anna Myriam Perrone;Donatella Santini;Elena Barbieri;Flora Guerra;Simona Ferrari;Claudio Zamagni;Pierandrea De Iaco;Giuseppe Gasparre;Daniela Turchetti. - In: BIOMED RESEARCH INTERNATIONAL. - ISSN 2314-6133. - ELETTRONICO. - 2014:787143(2014), pp. 1-11. [10.1155/2014/787143]
BRCA-Associated Ovarian Cancer: From Molecular Genetics to Risk Management
GIROLIMETTI, GIULIA;DE IACO, PIERANDREA;GASPARRE, GIUSEPPE;TURCHETTI, DANIELA
2014
Abstract
Ovarian cancer (OC) mostly arises sporadically, but a fraction of cases are associated with mutations in BRCA1 and BRCA2 genes. The presence of a BRCA mutation in OC patients has been suggested as a prognostic and predictive factor. In addition, the identification of asymptomatic carriers of such mutations offers an unprecedented opportunity for OC prevention. This review is aimed at exploring the current knowledge on epidemiological and molecular aspects of BRCA-associated OC predisposition, on pathology and clinical behavior of OC occurring in BRCA mutation carriers, and on the available options for managing asymptomatic carriers.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
